- Home
- LDI vs VERV Comparison
LDI vs VERV Comparison
Compare LDI & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- VERV
- Stock Information
- Founded
- LDI 2010
- VERV 2018
- Country
- LDI United States
- VERV United States
- Employees
- LDI N/A
- VERV N/A
- Industry
- LDI Finance: Consumer Services
- VERV Medicinal Chemicals and Botanical Products
- Sector
- LDI Finance
- VERV Health Care
- Exchange
- LDI Nasdaq
- VERV Nasdaq
- Market Cap
- LDI 402.7M
- VERV 382.5M
- IPO Year
- LDI 2021
- VERV 2021
- Fundamental
- Price
- LDI $2.35
- VERV $4.85
- Analyst Decision
- LDI Sell
- VERV Strong Buy
- Analyst Count
- LDI 3
- VERV 4
- Target Price
- LDI $2.60
- VERV $25.75
- AVG Volume (30 Days)
- LDI 959.0K
- VERV 1.6M
- Earning Date
- LDI 11-05-2024
- VERV 11-05-2024
- Dividend Yield
- LDI N/A
- VERV N/A
- EPS Growth
- LDI N/A
- VERV N/A
- EPS
- LDI N/A
- VERV N/A
- Revenue
- LDI $1,013,388,000.00
- VERV $24,396,000.00
- Revenue This Year
- LDI N/A
- VERV $84.66
- Revenue Next Year
- LDI $23.17
- VERV N/A
- P/E Ratio
- LDI N/A
- VERV N/A
- Revenue Growth
- LDI 10.36
- VERV 219.91
- 52 Week Low
- LDI $1.52
- VERV $4.31
- 52 Week High
- LDI $3.71
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- LDI 48.33
- VERV 40.26
- Support Level
- LDI $2.22
- VERV $4.44
- Resistance Level
- LDI $2.90
- VERV $4.93
- Average True Range (ATR)
- LDI 0.16
- VERV 0.48
- MACD
- LDI -0.02
- VERV -0.18
- Stochastic Oscillator
- LDI 35.84
- VERV 17.30
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.